This page will host Events plug-in for all Clarion and trade events.

Upcoming Events

View Calendar
Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.700 -0.090 (-3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,458,465
Open 2.790
Bid (Size) 2.690 (6)
Ask (Size) 2.740 (340)
Prev. Close 2.790
Today's Range 2.660 - 2.805
52wk Range 1.830 - 7.480
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
+5.1%
+5.1%
1 Month
+3.8%
+3.8%
3 Month
-10.3%
-10.3%
6 Month
+0.7%
+0.7%
1 Year
-57.3%
-57.3%

More News

Read More
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside
Via Stocktwits
Foot Locker And Archer Aviation Are Among Top 8 Mid-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?
Via Benzinga
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Via Benzinga
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
From ImmunityBio, Inc.
Via Business Wire
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
From ImmunityBio, Inc.
Via Business Wire
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ImmunityBio to Host Investor Day
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
Via Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Via Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Via Benzinga
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
From ImmunityBio, Inc.
Via Business Wire
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 2.700
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 06/27/25 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 1.06B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.